The Legal Examiner Mark The Legal Examiner Mark The Legal Examiner Mark search twitter facebook feed linkedin instagram google-plus avvo phone envelope checkmark mail-reply spinner error close
Skip to main content

Novartis AG has decided to delay it diabetes drug Galvus because of concerns with liver toxicity problems. The drug is supposed to compete favorably with Merck’s diabetes drug Januvia but problems with high dosage of Galvus has forced its delay to the market. Januvia is a once daily diabetes drug that works in a similar fashion to Galvus but doesn’t have the same liver toxicity concerns as Galvus.

For more information on this subject, please refer to the section on Drugs, Medical Devices, and Implants.

Comments are closed.

Of Interest